LIVIVO - Search results -

Search results

Result 1 - 10 of total 2230

Search options

Article ; Online: Alcohol consumption and the risk of renal cancers in the European Prospective Investigation into Cancer and Nutrition (EPIC). Wozniak MB, Brennan P, Brenner DR, Overvad K, Olsen A, Tjønneland A, Boutron-Ruault MC, Clavel-Chapelon F, Fagherazzi G, Katzke V, Kühn T, Boeing H, Bergmann MM, Steffen A, Naska A, Trichopoulou A, Trichopoulos D, Saieva C, Grioni S, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Peeters PH, Hjartåker A, Weiderpass E, Arriola L, Molina-Montes E, Duell EJ, Santiuste C, Alonso de la Torre R, Barricarte Gurrea A, Stocks T, Johansson M, Ljungberg B, Wareham N, Khaw KT, Travis RC, Cross AJ, Murphy N, Riboli E, Scelo G.Int J Cancer. 2015 Oct 15;137(8):1953-66. [Epub 2015 Apr 28]. doi: 10.1002/ijc.29559.

Jay, Raman / Brennan, P / Brenner / Overvad, K / Olsen, A / Tjønneland, A / Boutron-Ruault, M C / Clavel-Chapelon, F / Fagherazzi / Katzke, V / Kühn, T / Boeing, H / Bergmann, M M / Steffen, A / Naska, A / Trichopoulou, A / Trichopoulos, D / Saieva, C / Grioni, S /

Urologic oncology

2017 Volume 35, Issue 3, Page(s) 117

Abstract: Epidemiologic studies have reported that moderate alcohol consumption is inversely associated with the risk of renal cancer. However, there is no information available on the associations in renal cancer subsites. From 1992 to 2010, 477,325 men and women ...

Abstract	Epidemiologic studies have reported that moderate alcohol consumption is inversely associated with the risk of renal cancer. However, there is no information available on the associations in renal cancer subsites. From 1992 to 2010, 477,325 men and women in the European Prospective Investigation into Cancer and Nutrition cohort were followed for incident renal cancers (n = 931). Baseline and lifetime alcohol consumption was assessed by country-specific, validated dietary questionnaires. Information on past alcohol consumption was collected by lifestyle questionnaires. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated from Cox proportional hazard models. In multivariate analysis, total alcohol consumption at baseline was inversely associated with renal cancer; the HR and 95% CI for the increasing categories of total alcohol consumption at recruitment vs. the light drinkers category were 0.78 (0.62-0.99), 0.82 (0.64-1.04), 0.70 (0.55-0.90), and 0.91 (0.63-1.30), respectively, (ptrend = 0.001). A similar relationship was observed for average lifetime alcohol consumption and for all renal cancer subsites combined or for renal parenchyma subsite. The trend was not observed in hypertensive individuals and not significant in smokers. In conclusion, moderate alcohol consumption was associated with a decreased risk of renal cancer.
MeSH term(s)	Alcohol Drinking ; Female ; Humans ; Kidney Neoplasms ; Male ; Nutritional Status ; Proportional Hazards Models ; Prospective Studies ; Risk Factors
Language	English
Publishing date	2017-02-01
Publishing country	United States
Document type	Journal Article ; Comment
ZDB-ID	1336505-8
ISSN	1873-2496 ; 1078-1439
ISSN (online)	1873-2496
ISSN	1078-1439
DOI	10.1016/j.urolonc.2016.12.022
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4817: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Book: Telemanagement of inflammatory bowel disease

Cross, Raymond K. / Watson, Andrew R.

2015

Author's details	Raymond K. Cross ; Andrew R. Watson ed
Keywords	Inflammatory bowel diseases/Treatment ; Telecommunication in medicine
Subject code	616.34406
Language	English
Size	XII, 194 S. : Ill., graph. Darst., 24 cm
Publisher	Springer
Publishing place	Cham u.a.
Publishing country	Switzerland
Document type	Book
Note	Includes bibliographical references
HBZ-ID	HT018800084
ISBN	978-3-319-22284-4 ; 978-3-319-22285-1 ; 3-319-22284-8 ; 3-319-22285-6
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2015 A 3717	available for loan (reading room)	Lesesaal EG

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Synthetic biology, genetic circuits and machine learning: a new age of cancer therapy.

Prasad, Krishneel / Cross, Ryan S / Jenkins, Misty R

Molecular oncology

2023 Volume 17, Issue 6, Page(s) 946–949

Abstract: Synthetic biology has made it possible to rewire natural cellular responses to treat disease, notably demonstrated by chimeric antigen receptor (CAR) T cells as cancer immunotherapy. Building on the success of T-cell activation using synthetic receptors, ...

Abstract	Synthetic biology has made it possible to rewire natural cellular responses to treat disease, notably demonstrated by chimeric antigen receptor (CAR) T cells as cancer immunotherapy. Building on the success of T-cell activation using synthetic receptors, the field is now investigating how induction of noncanonical signalling pathways and sophisticated synthetic gene circuitry can enhance the antitumour phenotype of engineered T cells. This commentary explores two recently published studies that provide proof of concept for how new technologies achieve this. The first demonstrated that non-naturally occurring combinations of signalling motifs derived from various immune receptors and arranged as a CAR drove unique signal transduction pathways in T cells and improved their tumour killing ability. Here, machine learning complemented the screening process and successfully predicted CAR T-cell phenotype dependent on signalling motif choice. The second explored how synthetic zinc fingers can be engineered into controllable transcriptional regulators, where their activity was dependent on the presence or absence of FDA-approved small-molecule drugs. These studies are pivotal in expanding the design choices available for gene circuits of the future and highlight how a single cellular therapy could respond to multiple environmental cues including target cell antigen expression, the tumour microenvironment composition and small molecule drugs.
MeSH term(s)	Synthetic Biology ; Gene Regulatory Networks ; Machine Learning ; Receptors, Chimeric Antigen ; Immunotherapy, Adoptive ; Neoplasms/therapy ; Humans
Chemical Substances	Receptors, Chimeric Antigen
Language	English
Publishing date	2023-04-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	2415106-3
ISSN	1878-0261 ; 1574-7891
ISSN (online)	1878-0261
ISSN	1574-7891
DOI	10.1002/1878-0261.13420
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6637: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: 96 Evaluation of prolonged hay net use on the rostral oral cavity and salvia production in adult horses

Cross, T.D. / Locke, M.R. / Guay, K.A. / Martinez, R.E. / Wellmann, K. / Jones, T.N.

Journal of Equine Veterinary Science. 2023 May, v. 124 p.104398-

2023

Abstract: ... of the sublingual gland. Statistics were formulated using 3-way repeated measures ANOVA using R Statistical Program® ...

Abstract	Previous hay net studies have focused on behavior, consumption, and feed wastage; yet none have evaluated effects in the oral cavity. To investigate the effects of prolonged hay net use on rostral soft tissue and saliva production, 8 stock-type horses were evaluated for dental health and floated by a dental technician to ensure consistency. Horses were blocked by body weight (BW; 558.6 ± 13.8kg), body condition (BC; 6.5 ± 0.2), sex (mares: n = 5; geldings: n = 3), and age (10.1 ± 1.1yr) and randomly assigned to one of 2 feeding treatments for 70d. Horses on control (CON; n = 4) were offered loose hay in a tub; horses in the experimental group (NET; n = 4) were offered hay encased in a slow-feeder hay net (Texas Hay Net, 3.81cm² openings). Horses received coastal bermudagrass hay at 1.5% of BW daily along with a commercial concentrate (Equilene® Pellets) at ≤0.7% of BW as-fed to maintain BC. Horses were kept in individual dry pens with access to feed, water, and salt for 16 h/day, and then group-housed in dry lots with only ad-libitum water and salt for 8hr/day. Feed intake was recorded daily by the collection and weighing of orts. All horses were assessed weekly using digital and thermography (FLIR®) images to document changes in rostral oral tissue. Blind reviewers analyzed images for changes in rostral oral cavity scores (ROCS) ranging from no damage (ROCS = 7) to severe damage (ROCS = 21).Biweekly saliva measurements were taken immediately before hay offering and 1hr after consumption using 2 disposable oral swabs (Munkcare®, 18cm³ each) held at the exit of the sublingual gland. Statistics were formulated using 3-way repeated measures ANOVA using R Statistical Program®. Intake was not influenced by feeding method (P = 0.874), nor was saliva production (P = 0.570). NET horses had numerically higher pre-consumption saliva values (5.27 ± 0.41g) compared with CON horses (4.55 ± 0.49g). Saliva production increased post-1hr consumption (P ≤ 0.001) confirming production was a result of mastication. The surface temperature of the oral cavity was not affected by treatment (P = 0.471) and was within normal ranges. Average total ROCS did not differ between treatments (NET: 11.0 ± 0.2; CON: 12.2 ± 0.2; P = 0.251) but increased with time (P ≤ 0.01). Use of a hay net for 70d did not influence intake or negatively affect rostral tissue, indicating a level of safety long-term. Based on these findings, feeding from a hay net over a 1hr period did not influence saliva production; however, in future studies, saliva production should be evaluated over an entire consumption period.
Keywords	adults ; body condition ; body weight ; dental health ; feed intake ; group housing ; hay ; horses ; mastication ; mouth ; saliva ; statistics ; surface temperature ; thermography ; tissues ; veterinary medicine ; Texas
Language	English
Dates of publication	2023-05
Publishing place	Elsevier Inc.
Document type	Article ; Online
ZDB-ID	2102631-2
ISSN	1542-7412 ; 0737-0806
ISSN (online)	1542-7412
ISSN	0737-0806
DOI	10.1016/j.jevs.2023.104398
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article ; Online: Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases.

Kay, Jonathan / Cross, Raymond K / Feldman, Steven R / Park, Younjin / Hanauer, Stephen B

Advances in therapy

2023 Volume 41, Issue 2, Page(s) 509–533

Abstract: SB5 is an approved biosimilar of adalimumab, a recombinant monoclonal anti-tumor necrosis factor (TNF) antibody. The approval of SB5 was based on the comparison with reference adalimumab in analytical studies, pharmacokinetic (PK) and immunogenicity ... ...

Abstract	SB5 is an approved biosimilar of adalimumab, a recombinant monoclonal anti-tumor necrosis factor (TNF) antibody. The approval of SB5 was based on the comparison with reference adalimumab in analytical studies, pharmacokinetic (PK) and immunogenicity assessments, and randomized controlled trials. Efficacy data was primarily obtained in patients with rheumatoid arthritis, and extended to include additional indications such as psoriasis, Crohn's disease, or ulcerative colitis by extrapolation. Following its approval, additional post-marketing data have been collected comparing SB5 with reference adalimumab. This review summarizes the clinical data on SB5 from randomized controlled trials and provides a comprehensive overview of the available post-approval data. In "real-world" settings, SB5 was as effective as its reference product across different indications and countries, treatment persistence was well maintained throughout studies, and no new safety concerns were identified. In both controlled and "real-world" settings, switching from reference adalimumab to SB5 was not associated with altered efficacy or clinical complications. In post-approval studies, the quality of SB5 was consistent over time, independent of the batch and process changes, and the SB5 autoinjector was preferred over other autoinjectors by both healthcare professionals and patients. Taken together, these data support the use of SB5 whenever reference adalimumab is appropriate and demonstrate that switching from reference adalimumab to SB5 is feasible.
MeSH term(s)	Humans ; Adalimumab/therapeutic use ; Biosimilar Pharmaceuticals/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Crohn Disease/drug therapy ; Tumor Necrosis Factor-alpha/therapeutic use ; Treatment Outcome
Chemical Substances	Adalimumab (FYS6T7F842) ; Biosimilar Pharmaceuticals ; Tumor Necrosis Factor-alpha
Language	English
Publishing date	2023-12-19
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	632651-1
ISSN	1865-8652 ; 0741-238X
ISSN (online)	1865-8652
ISSN	0741-238X
DOI	10.1007/s12325-023-02737-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2101: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Medical device report analyses from MAUDE: Device and patient outcomes, adverse events, and sex-based differential effects.

Liao, Tsung-Jen / Crosby, Lynn / Cross, Kevin / Chen, Minjun / Elespuru, Rosalie

Regulatory toxicology and pharmacology : RTP

2024 Volume 149, Page(s) 105591

Abstract: Post-market medical device-associated failures and patient problems are reported in Medical Device Reports (MDRs) to the US Food and Drug Administration. Reports are accessible through Manufacturer and User Facility Device Experience (MAUDE), a database ... ...

Abstract	Post-market medical device-associated failures and patient problems are reported in Medical Device Reports (MDRs) to the US Food and Drug Administration. Reports are accessible through Manufacturer and User Facility Device Experience (MAUDE), a database including both required and voluntary submissions. We present an overview of >10 million MDRs received from 2011 to 2021. Approximately 92% of reporting issues represent medical device physical or functional failures, categorized from 1704 codes related to medical device integrity or function. ∼8% were coded adverse events (AEs). Patient outcomes are reported via 998 patient codes in 19 medical specialties (cardiovascular, orthopedic, etc.). ∼40% of patient reports indicated "no health consequences"; however, a small number of devices had consistently high AE reports. While overall reports did not exhibit a sex-based dichotomy, ∼9% of the reported AEs occurred more frequently in females, many of which were related to immune effects. The analyses are subject to uncertainties and potential bias based on data available and data selected for analysis. However, such an overview of post-market MDR data, not previously published, fills a gap in understanding medical device issues and patient-based outcomes related to medical device use. Trends identified may be subjects of additional hypotheses, analysis, and research.
MeSH term(s)	Humans ; Female ; United States ; Product Surveillance, Postmarketing ; Equipment and Supplies/adverse effects ; Male ; United States Food and Drug Administration ; Databases, Factual ; Sex Factors ; Equipment Failure
Language	English
Publishing date	2024-03-11
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	604672-1
ISSN	1096-0295 ; 0273-2300
ISSN (online)	1096-0295
ISSN	0273-2300
DOI	10.1016/j.yrtph.2024.105591
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1711: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: National Survey of Non-Consultant Hospital Doctors' Awareness & Attitudes towards Smoking Cessation Interventions in the Outpatient Setting.

Power Foley, M / Fahy, R / Khan, T / Gosi, G / McGonagle, M P / Simon Cross, K

Irish medical journal

2023 Volume 116, Issue 5, Page(s) 778

MeSH term(s)	Humans ; Smoking Cessation ; Outpatients ; Hospitals ; Attitude of Health Personnel ; Surveys and Questionnaires
Language	English
Publishing date	2023-05-18
Publishing country	Ireland
Document type	Letter
ZDB-ID	193134-9
ISSN	0332-3102 ; 0021-129X
ISSN	0332-3102 ; 0021-129X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 148: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Introducing Routine Assessment of Adverse Childhood Experiences For Looked-After Children: The Use and Properties of the Trauma and Adverse Life Events (TALE) Screening Tool.

Kerr-Davis, Asa / Hillman, Saul / Anderson, Katharine / Cross, Richard

Journal of child & adolescent trauma

2023 Volume 16, Issue 4, Page(s) 981–994

Abstract: The present study aims to illustrate the process of developing, implementing, and clinically validating a new assessment measure, the Trauma and Adverse Life Events (TALE) screening tool, to assess Adverse Childhood Experiences (ACEs) among looked-after ... ...

Abstract	The present study aims to illustrate the process of developing, implementing, and clinically validating a new assessment measure, the Trauma and Adverse Life Events (TALE) screening tool, to assess Adverse Childhood Experiences (ACEs) among looked-after children. The TALE was developed by adapting existing ACEs measures to reflect the experiences of looked-after children. The TALE was completed by the local authority social worker for 218 children placed with Five Rivers Child Care (a UK fostering agency, residential, and educational care provider). Reliability was examined and exploratory factor analysis was conducted. Correlations between TALE scores, background variables, and psychosocial wellbeing using the carer-report Strengths and Difficulties Questionnaire (SDQ) and Child Dissociative Checklist (CDC) were also explored. The TALE was found to have acceptable reliability (
Language	English
Publishing date	2023-06-28
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2502136-9
ISSN	1936-153X ; 1936-1521
ISSN (online)	1936-153X
ISSN	1936-1521
DOI	10.1007/s40653-023-00559-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Assessing vaccine-mediated protection in an ultra-low dose

Plumlee, C R / Barrett, H W / Shao, D E / Lien, K A / Cross, L M / Cohen, S B / Edlefsen, P T / Urdahl, K B

bioRxiv : the preprint server for biology

2023

Abstract: Despite widespread immunization with Bacille-Calmette-Guerin (BCG), the only currently licensed tuberculosis (TB) vaccine, TB remains a leading cause of mortality globally. There are many TB vaccine candidates in the developmental pipeline, but the lack ... ...

Abstract	Despite widespread immunization with Bacille-Calmette-Guerin (BCG), the only currently licensed tuberculosis (TB) vaccine, TB remains a leading cause of mortality globally. There are many TB vaccine candidates in the developmental pipeline, but the lack of a robust animal model to assess vaccine efficacy has hindered our ability to prioritize candidates for human clinical trials. Here we use a murine ultra-low dose (ULD)
Language	English
Publishing date	2023-06-16
Publishing country	United States
Document type	Preprint
DOI	10.1101/2023.03.22.533820
Database	MEDical Literature Analysis and Retrieval System OnLINE

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Enhancing preclinical drug discovery with artificial intelligence.

Vijayan, R S K / Kihlberg, Jan / Cross, Jason B / Poongavanam, Vasanthanathan

Drug discovery today

2021 Volume 27, Issue 4, Page(s) 967–984

Abstract: Artificial intelligence (AI) is becoming an integral part of drug discovery. It has the potential to deliver across the drug discovery and development value chain, starting from target identification and reaching through clinical development. In this ... ...

Abstract	Artificial intelligence (AI) is becoming an integral part of drug discovery. It has the potential to deliver across the drug discovery and development value chain, starting from target identification and reaching through clinical development. In this review, we provide an overview of current AI technologies and a glimpse of how AI is reimagining preclinical drug discovery by highlighting examples where AI has made a real impact. Considering the excitement and hyperbole surrounding AI in drug discovery, we aim to present a realistic view by discussing both opportunities and challenges in adopting AI in drug discovery.
MeSH term(s)	Artificial Intelligence ; Drug Discovery ; Machine Learning
Language	English
Publishing date	2021-11-25
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1324988-5
ISSN	1878-5832 ; 1359-6446
ISSN (online)	1878-5832
ISSN	1359-6446
DOI	10.1016/j.drudis.2021.11.023
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4725: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito